Brief: Lumos Pharma Says Has Had To Re-Evaluate Timing Of Phase 2B Clinical Trial For Product Candidate LUM-201
14/05/2020 22:47
May 14 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA INC - HAS HAD TO RE-EVALUATE TIMING OF ITS
PHASE 2B
CLINICAL TRIAL FOR ITS PRODUCT CANDIDATE LUM-201
* LUMOS PHARMA INC - NOW EXPECTS TO INITIATE ITS PHASE 2B
TRIAL IN
PEDIATRIC GROWTH HORMONE DEFICIENCY PRIOR TO END OF 2020
Source text: (https://bit.ly/2X11qh8)
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)